logo
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers

QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers

Results demonstrated statistically significant effects on biomarkers that predict ALS disease progression and severity
Evidence of brain penetration, target engagement, and potential anti-seizure effects demonstrated through biomarkers for TMS-EMG and EEG
Safety and tolerability profile consistent with previously reported results for QRL-101
QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy
CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis Corporation ('QurAlis'), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced positive topline data from QurAlis' Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101 in healthy volunteers evaluating biomarkers related to amyotrophic lateral sclerosis (ALS) and epilepsy.
Topline results demonstrated a dose-dependent, statistically significant decrease in motor nerve excitability threshold tracking (mNETT) strength-duration time constant (SDTC), the co-primary endpoint of the trial related to ALS. SDTC is a well-established electrophysiological biomarker of peripheral motor excitability related to ALS, where elevation of SDTC has been clinically shown to predict faster disease progression and mortality. The decrease in SDTC observed with QRL-101 in this study was approximately 50% greater than previously reported for the Kv7 potassium channel opener ezogabine in a single-dose study in people with ALS. Additional observations for multiple secondary and exploratory endpoints related to motor nerve excitability were also significantly impacted.
The clinical trial demonstrated a statistically significant impact on multiple secondary and exploratory endpoints related to epilepsy. These included transcranial magnetic stimulation electromyography (TMS-EMG) intracortical facilitation which indicates effective inhibition of cortical excitability, as well as significant increases in electroencephalography (EEG) spectral power in beta and gamma spectral bands further demonstrating cortical target engagement and brain penetration. There was minimal to no impact on the slower delta and theta EEG bands, which suggests a low potential for GABA-A receptor activation and sedation. The study did not reach statistical significance on the co-primary endpoint of TMS-EMG motor evoked potential (MEP) amplitude, another measure of corticospinal excitability.
Results also demonstrated that the safety and tolerability profile of QRL-101 was consistent with previously reported study results evaluating QRL-101 to date. There were no serious adverse events or discontinuations due to adverse events reported observed in the study.
'We are excited by these topline data from our biomarker study in healthy participants which suggest that QRL-101 has the potential to provide a therapeutic effect for both ALS and epilepsy,' said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. 'Loss of Kv7.2/7.3 function from the mis-splicing of the KCNQ2 gene leading to hyperexcitability-induced neurodegeneration was one of the first genetic breakthroughs from human ALS motor neuron stem cell models made by our founders at Harvard. QurAlis was started to develop a best-in-class Kv7 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in about half of all people living with ALS. Elevated SDTC has been clinically linked to faster disease progression and mortality, underscoring the need for an effective treatment for this population.'
Dr. Roet continued, 'The decrease in SDTC observed with QRL-101 in this study was approximately 50% greater than previously reported for the Kv7 opener ezogabine in a single-dose study in people with ALS. QRL-101 has the potential to be a promising therapeutic, especially considering the encouraging results from a previous study with ezogabine in ALS patients showing positive effects on both SDTC and the disease progression biomarker compound muscle action potential (CMAP). Further, based on the strong clinical validation of Kv7.2/7.3 ion channel openers in seizure reduction, the TMS-EMG intracortical facilitation together with the EEG data from this study suggest QRL-101 may have the potential to reduce both frequency and severity of seizures in people living with epilepsy without causing sedation. We are encouraged by these results and look forward to advancing the clinical program for QRL-101 in both ALS and epilepsy so that we can fulfill our mission of bringing much-needed precision medicine options to patients.'
Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of both neuronal excitability and membrane potential. QRL-101 is a potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in both sporadic and genetic forms of ALS, with the majority caused by the mis-splicing of the KCNQ2 gene in the pre-mRNA. Kv7 is also a clinically validated target to regulate the hyperexcitable state in epilepsy. In vivo and in vitro studies have demonstrated that QRL-101 is more potent in threshold track studies and exhibits the potential for fewer clinical adverse events that ezogabine, a less selective, first-generation, Kv7.2/7.3 channel opener.
The Phase 1 PoM study (QRL-101-05, NCT06681441) was a randomized, double-blind, placebo-controlled, three-way crossover trial. The study was conducted at the Centre for Human Drug Research, an early-phase Contract Research Organization based in Leiden, The Netherlands. The study evaluated two dose levels of QRL-101 versus placebo in healthy volunteers, assessing:
Additional QRL-101 clinical trials include:
QRL-101-01 (NCT05667779) was a first-in-human, single-ascending dose clinical trial in 88 healthy participants. In this clinical trial, QRL-101 was shown to be well tolerated. The study completed in late 2023 and results from QRL-101-01 supported a tolerable dose range for subsequent studies.
QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy participants.
QRL-101-04 (NCT06714396) is a Phase 1 PoM single-dose, placebo-controlled clinical trial designed to evaluate the safety and tolerability of QRL-101 in people living with ALS. QRL-101-04 is expected to enroll approximately 12 participants with ALS and will evaluate the impact of QRL-101 on mNETT.
QRL-101-06 is a Phase 1 randomized, open-label, single dose, cross-over study to evaluate the PK of three formulations of QRL-101 in a fasted condition or in the presence of a high fat meal in healthy participants.
More information about the QRL-101 clinical trials can be found at www.clinicaltrials.gov.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AIDCF Releases Landmark Report Highlighting Job Loss Crisis and Urges for Urgent Reforms in India's Cable TV Sector
AIDCF Releases Landmark Report Highlighting Job Loss Crisis and Urges for Urgent Reforms in India's Cable TV Sector

Business Upturn

time27 minutes ago

  • Business Upturn

AIDCF Releases Landmark Report Highlighting Job Loss Crisis and Urges for Urgent Reforms in India's Cable TV Sector

NEW DELHI , June 10, 2025 /PRNewswire/ — All India Digital Cable Federation today launched a landmark study titled ' State of Cable TV Distribution in India ' . Developed in collaboration with EY India, the report offers critical insights into the challenges, evolution, and future of India's cable television ecosystem. It brings together extensive field data and sectoral analysis to present a comprehensive view of the Cable TV distribution landscape. Based on inputs from over 28,000 Local Cable Operators (LCOs) across India , the report highlights a sharp decline in cable TV subscriptions—driven by rising channel costs and competition from unregulated platforms—which, in turn, has led to a significant employment crisis. Key findings of the report include: The workforce of surveyed LCOs declined by 31% since 2018 , with a reported loss of 37,835 jobs . When extrapolated nationally, the estimated job loss ranges between 1.14 lakh and 1.95 lakh . , with a reported loss of . When extrapolated nationally, the estimated job loss ranges between . Pay TV households declined by 40 million , from 151 million in 2018 to 111 million in 2024. , from 151 million in 2018 to 111 million in 2024. 93% LCOs reported a decline in their subscriber base since 2018; LCOs reported a since 2018; 49% of LCOs reported a drop in their monthly income . of LCOs reported a . 35% reported subscriber loss of over 40%. Key reforms suggested by the report include: Enabling of level-playing field across all content distribution mediums across all content distribution mediums Permitting differential pay TV pricing for different territories based on ability to pay for different territories based on ability to pay Activating over 20 million inactive STBs in India Restrict or limit the provision of live or slightly delayed transmission of pay TV content for free on other platforms Take a unified stand against piracy Mr. Sanjiv Shankar, Additional Secretary, Ministry of Consumer Affairs; Former Joint Secretary, Ministry of Information and Broadcasting, shared his remarks: 'This report is truly one of its kind—comprehensive, data-driven, and grounded in the realities of the ground-level cable ecosystem. It brings into focus the structural shifts and challenges within the sector, and provides a valuable evidence base for future policy-making.' Mr. S.N. Sharma, CEO of DEN Networks Limited and President of AIDCF, expressed his enthusiasm about the report: 'This report is perhaps the most comprehensive bottom-up view of the Pay TV distribution sector in recent times.' 'The report presents not just statistics but stories of lost livelihood impacting families and entrepreneurship, and they need be heard across the broadcasting ecosystem.' 'While the report presents conservative estimates, the situation is even more grave. When factoring in the closure of approximately 900 MSOs and 72,000 LCOs over the past six years, the total cumulative job loss is estimated to exceed 5.77 lakh.' 'We urge all stakeholders — including broadcasters, regulators, and our parent ministry — to use the report as a base to bring practical reforms and support the cable TV industry to thrive once again.' Mr. Ashish Pherwani, Partner, Media & Entertainment Sector, EY India, remarked that: 'This is a first-of-its-kind report that captures the true pulse of the cable TV distribution network in India . Its scale, depth of field data, and insight into last-mile realities make it a valuable resource for both industry and policymakers alike.' The report was released during a special event held at Shangri-La Eros, New Delhi , where senior policymakers, industry leaders, and key stakeholders from across the broadcasting and media landscape came together to deliberate on the findings and implications of this industry-first report. The report can be accessed from AIDCF's official website or by clicking on this link. About All India Digital Cable Federation (AIDCF) All India Digital Cable Federation is the apex body for Digital Multi-System Operators (MSOs) in India . AIDCF is the official voice for the Indian digital cable TV industry and works towards the overall growth of the sector. AIDCF has consistently championed the interests of the cable TV distribution industry and remains committed to promoting a fair, competitive, and sustainable broadcasting ecosystem. The members of the federation have a combined market share of > 65%. Members of AIDCF includes Asianet Satellite Communications Limited, DEN Networks Limited, Fastway Transmission Private Limited, GTPL Hathway Private Limited, Hathway Cable & Datacom Limited, Kerala Communicators Cable Limited, NXT Digital, SITI Cable Network Limited and UCN Cable Network Private Limited. Photo: View original content to download multimedia: Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.

Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025

Yahoo

time30 minutes ago

  • Yahoo

Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025

Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. For the first time at an international conference, Caliway will share preclinical results on CBL-514's potential new indication: combined with GLP-1 therapies to prevent post-treatment weight rebound. NEW TAIPEI CITY, June 10, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) announced today its participation in the 2025 BIO International Convention, to be held from June 16 to 19 in Boston, U.S.A. Caliway's Vice President, April Yuan, will deliver an oral presentation on June 17, highlighting the company's latest progress in R&D and pipeline development. The presentation will cover recent updates on CBL-514, first-in-class injectable drug candidate for large-area, site-specific fat reduction, including its development across multiple indications—subcutaneous fat reduction, cellulite, and Dercum's disease. For the first time at an international conference, Caliway will also share preclinical data on a potential new indication: weight rebound management through a combination therapy with GLP-1 receptor agonists. As GLP-1 receptor agonists gain widespread use globally, post-discontinuation weight rebound has become a significant, yet unmet clinical concern. According to published studies, only 10% of patients are able to maintain weight loss after stopping GLP-1 treatment. Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate — suggesting that CBL-514 may help maintain weight loss outcomes after GLP-1 therapy. CBL-514 works by directly targeting the root cause—subcutaneous fat—through selective induction of adipocyte apoptosis. It may serve as a complementary combination therapy to GLP-1s, pairing systemic weight loss with precise body contouring. Caliway plans to submit a Phase 2 IND application to the U.S. FDA for this new indication in Q4 2025. "We believe post-weight-loss weight rebound is a promising unmet market need," said Vivian Ling, CEO of Caliway. "CBL-514 has the potential to serve as a complementary combination therapy with GLP-1 treatments — with GLP-1s driving weight reduction, and CBL-514 reshaping and maintaining outcomes through localized fat reduction, enhancing the overall treatment impact and long-term value." The BIO International Convention is the world's largest and most influential biotechnology event, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation exchange, and investment. Caliway Presentation at BIO 2025: Date & Time: Tuesday, June 17, 2025 | 11:45 AM – 12:00 PM (EDT) Location: Room 154 | Boston Convention & Exhibition Center Speaker: April Yuan, VP, Caliway Biopharmaceuticals Session Info: About CBL-514CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world's first injectable lipolysis drug that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas without causing any systemic side effects on the central nervous system, cardiovascular system, and respiratory system. As of May 2025, 10 clinical trials with a total of 520 subjects have been completed with all efficacy and safety endpoints met. Caliway is currently investigating multiple indications for CBL-514, including non-surgical fat reduction, moderate-to-severe cellulite, and weight rebound management through a combination therapy with GLP-1-based treatments. CBL-514D, the same active pharmaceutical ingredients (APIs) but under different formulation, is being studied for additional indications such as Dercum's disease and more. About Caliway BiopharmaceuticalsCaliway Biopharmaceuticals (Caliway) is a clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the Taiwan Exchange (TWSE-6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and other diseases. For more information, please visit: DisclaimerThis article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change. View original content to download multimedia: SOURCE Caliway Biopharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nordic Breakthrough for Unlimited Fossil-Free Energy - NOVATRON 1 Officially Inaugurated
Nordic Breakthrough for Unlimited Fossil-Free Energy - NOVATRON 1 Officially Inaugurated

Yahoo

time30 minutes ago

  • Yahoo

Nordic Breakthrough for Unlimited Fossil-Free Energy - NOVATRON 1 Officially Inaugurated

STOCKHOLM, June 10, 2025 /PRNewswire/ -- On June 9, NOVATRON 1 was officially inaugurated at the Royal Institute of Technology (KTH) in Stockholm - the EU's first private, fully integrated fusion plasma system. The event marks a historic milestone for Sweden and the Nordic region in the development of commercial fusion energy. With Novatron Fusion Group (NFG) leading the charge, the Nordics are uniquely positioned to shape the future of energy through innovation, collaboration, and technological leadership. Fusion technology has the potential to address some of the most pressing global challenges of our time - from climate change to growing energy demand. Realizing this potential requires cross-sector collaboration between industry, academia, and policymakers. NFG is actively working to establish a strong Nordic fusion cluster and position the region as a driving force in the transition to a sustainable energy future. The inauguration brought together representatives from across the Nordic innovation ecosystem - including industry, academia, and government - with nearly all parties from the Swedish Parliament's Energy Committee in attendance. The broad participation underscores the strong support for fusion's role in the future energy mix. - The inauguration of NOVATRON 1 is a milestone - not only for our company but for the entire Nordic region. We're showing that it's possible to take concrete steps toward commercial fusion energy here and now. Our vision is that the Nordics will realize fusion, and today's event is powerful proof that we're on the right path, says Peter Roos, CEO of Novatron Fusion Group. Fusion energy - often referred to as "The Holy Grail of Energy" - has the potential to deliver continuous, safe, and fossil-free baseload power. As one of Europe's leading fusion companies, NFG is not only advancing fusion energy in the Nordics but also helping to strengthen Europe's energy resilience. At a time when G7 nations are highlighting fusion as a strategic solution to the climate crisis and energy security, European independence and cooperation in the energy sector are more important than ever. - NFG's groundbreaking technology is a vital contribution from Sweden to Europe's energy independence and climate transition, says Professor Christer Fuglesang, KTH Space Center. The NOVATRON concept is based on a unique design by innovator Jan Jäderberg and has been developed by a world-class team of physicists, engineers, and researchers. The technology addresses one of the biggest challenges in commercial fusion: stable and continuous confinement of fusion plasma without interruptions in energy production. This is described in more detail in a scientific article published last week, which highlights, among other things, NOVATRON's potential to achieve groundbreaking energy exchange values. With this promising concept, NFG aims to provide cost-effective and globally scalable baseload power to the grid within the next decade. During the inauguration, visitors witnessed a live plasma experiment in the prototype facility - the Nordic region's first step toward a commercial fusion reactor and a fossil-free society. - We believe that NFG has a game changing formula and as an owner with a long-term mindset, we're excited to help accelerate the work towards limitless fossil-free energy, says Henrikki Talvitie, CEO of St1. For more information, please contact:Jeanette MattssonMarketing and Communications Director, Novatron Fusion GroupEmail: Phone: +46 76 051 75 16 This information was brought to you by Cision The following files are available for download: NFG press release Peter Roos, CEO of NFG Prof. Christer Fuglesang Swedish Parliament's Energy Committee and CEO of NFG View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store